```
prompt_version: stage1-v184-20260502 / turn2
```

---

target_title:   Enantioselective and Enantiospecific Transition-Metal-Catalyzed Cross-Coupling Reactions of Organometallic Reagents To Construct C−C Bonds
target_authors: Alan H. Cherney, Nathaniel T. Kadunce, and Sarah E. Reisman
target_start:   page 1 (9587)
target_end:     end of document (page 66 / p. 9652)

---

## [Turn 2: Agent V2]

field: Target-oriented synthesis and medicinal/natural-product chemistry — application of stereocontrolled cross-coupling to the synthesis of biologically active and structurally complex molecules [preempts_turn3_default: no]

field_rationale: V1 operated entirely within the catalytic-mechanism and selectivity-origin frame: its 15 questions address KR vs. DYKAT assignments, radical clock validation, Ni¹/Ni³ intermediacy, precoordination intermediates, transmetalation TS geometry, and kinetic characterization. None of V1's questions ask whether the stereochemical methods described are *useful for preparing real targets*, whether ee values achieved on model substrates survive when applied to multifunctional natural product intermediates, whether catalyst loadings and conditions are compatible with complex molecular settings, or which biological questions the accessible stereocenters are intended to answer. Target-oriented synthesis and medicinal chemistry generate a wholly different kind of question: not "what is the rate-determining step?" but [REDACTED: substantial verbatim quotation; see Tier 9] The review describes itself as covering methods that have "revolutionized synthetic planning and practice" and enable access to "many bioactive small molecules and natural product targets" (Conclusion), yet it provides no systematic audit of which targets have been made, whether the enabling step was the asymmetric coupling, how many total syntheses actually relied on these methods as the key step, or what the therapeutic/biological context of the stereocenters is. This gap is invisible from V1's perspective and requires the target-oriented lens.

**Selectivity trigger check (mandatory):** The review contains extensive selectivity data (ee, es, dr, regio- and chemoselectivity) throughout. V1 addressed kinetic vs. thermodynamic selectivity questions in several places (V1-Q6 on KR/DKR, V1-Q7 on rate-determining steps). V2 must check for additional selectivity questions of a different type not covered by V1. The target-synthesis lens generates: [REDACTED: substantial verbatim quotation; see Tier 9] — this is a complexity-tolerance question, not a kinetic-vs.-thermodynamic question. See V2-Q4 below.

---

### --- New questions ---

**V2-Q1**

loc: P66:Lcol:1-30 (p. 9640, Section 6 "Conclusion and Future Outlook," final paragraph)

quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: The Conclusion identifies vicinal tertiary centers and all-carbon quaternary centers as targets of "many bioactive small molecules," but the review provides no inventory of which specific natural products or drug candidates bearing these motifs have been targeted and whether any currently lack an enantioselective cross-coupling route in their synthesis. Without such an inventory, the statement "present in many bioactive small molecules" is an assertion rather than a demonstrated need. Which specific natural product or pharmaceutical targets bearing vicinal tertiary or quaternary centers remain inaccessible because enantiocontrolled cross-coupling of two sec-alkyl partners is unavailable, and what is the biological or therapeutic justification for prioritizing these targets over others?

severity: medium

inference_tier: T2 [paper-grounded inference]

---

**V2-Q2**

loc: P17:Rcol:1-20 (p. 9603, section 3.1.2 Organotin Reagents, synthesis of (+)-goniofuturone; Scheme 9a)

quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: Scheme 9a (the total synthesis of (+)-goniofuturone) is one of the very few examples in the review where an enantiospecific Stille cross-coupling was deployed as the key step in a natural product synthesis. The review does not report the total yield over the synthesis, the number of steps, whether other key stereocenters in the target were set by cross-coupling or by other means, or whether the asymmetric coupling step represented the selectivity bottleneck. How many of the 427 cited references actually report the use of an enantiocontrolled cross-coupling as the *key stereodetermining step* in a total synthesis of a natural product or pharmaceutical agent, and what fraction of those targets are biologically validated (i.e., have demonstrated bioactivity assays reported)?

severity: high

inference_tier: T2 [paper-grounded inference]

---

**V2-Q3**

loc: P8:Rcol:10-25 (p. 9594, section 2.2.2 With Organozinc Reagents, Fu group coupling of 1-bromoindane 32 and alkylzinc with Ni/L38; Figure 14b)

quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: The chiral indane motif (33a–33c) is present in numerous bioactive natural products and pharmaceuticals (e.g., physostigmine, herbindole alkaloids, several kinase inhibitors), and indane 33a (96% ee) represents an attractive synthetic intermediate. However, the review reports only a single example of this coupling (1-bromoindane + RZnBr) without demonstrating that the product can be elaborated toward a specific natural product target or that functional groups required in the target (e.g., free amine, carbonyl, heteroatom) are tolerated by the Ni/L38 catalyst. Has the Ni/L38-catalyzed enantioselective coupling of 1-bromoindanes been applied in a total synthesis, and if so, what is the functional group tolerance profile relevant to downstream elaboration?

severity: medium

inference_tier: T2 [paper-grounded inference]

---

**V2-Q4**

loc: P11:Rcol:15-30 (p. 9597, section 2.2.3 With Organoboron Reagents, Fu group α-chloroamide Suzuki–Miyaura with Ni/L45; Figures 21–22)

quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: The review demonstrates high ee values (90–94% ee) for the Ni-catalyzed stereoconvergent Suzuki–Miyaura cross-coupling of secondary alkyl halides bearing directing groups (carbamates, sulfonamides, halohydrins) in simple, monofunctional substrates. A fundamental question for target-oriented synthesis is whether these directing-group-dependent ee values are maintained in more complex intermediates where a remote stereocenter, ring strain, or additional coordinating groups might interfere with the chiral environment of the Ni catalyst. Is there evidence — from synthesis of any complex natural product or pharmaceutical intermediate — that the ee values (≥90%) reported for model substrates in Figures 20–22 are preserved when the coupling is applied late-stage in a multistep synthesis?

severity: high

inference_tier: T2 [paper-grounded inference]

---

**V2-Q5**

loc: P12:Lcol:1-20 (p. 9598, section 2.2.3 organoboron, Ni/Ir dual catalysis; Figure 11 discussion)

quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: The Ni/Ir dual catalysis cross-coupling (Figure 11, 52% yield, 50% ee) represents a proof of concept for radical-mediated enantioselective C(sp³)–C(sp²) bond formation using organoboron reagents. A complementary question from the target-synthesis perspective is: what class of target molecules would *uniquely* require this Ni/Ir approach rather than conventional polar two-electron cross-coupling? Specifically, are there natural product targets or drug scaffolds containing benzylic or α-amino stereocenters whose synthesis would benefit from the radical mechanism (e.g., because the substrate is incompatible with strongly basic conditions, or because the electrophile is an unactivated alkyl halide intolerant of other cross-coupling protocols)? Has the Ni/Ir approach been applied to any target synthesis even at the model substrate level beyond compound 23?

severity: medium

inference_tier: T2 [paper-grounded inference]

---

**V2-Q6**

loc: P20:Lcol:1-25 (p. 9606, section 2.3.2, Ni/Ir cascade cyclization/cross-coupling; Figure 23)

quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: The cascade cyclization/cross-coupling (Figure 23, Ni/L46, product 66c: 53% yield, 99:1 dr, excellent ee) is described as "remarkable" for its ability to set two stereocenters in a single catalytic step. From a target-synthesis perspective, the key question is whether this cascade has been applied to any natural product target bearing the bicyclic framework produced, and whether the benzofuranoid skeleton of products 66a–66c maps onto any biologically validated natural product. What is the demonstrated scope of this cascade in terms of the complexity of the electrophile component, and has it been applied beyond simple alkyl bromides and the benzofuranyl substrate class?

severity: medium

inference_tier: T2 [paper-grounded inference]

---

**V2-Q7**

loc: P32:Rcol:10-30 (p. 9618, section 4.1.1, Cu-catalyzed asymmetric allylic substitution of cinnamyl electrophiles; Figure 61)

quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: The Cu-catalyzed asymmetric allylic alkylation of cinnamyl electrophiles with organomagnesium reagents has been optimized with numerous ligands (L72–L79, Figure 61) delivering 88–>99% ee with various Grignard reagents. From a target-synthesis standpoint, cinnamyl-derived allylic stereocenters are present in a wide range of terpenoid and polyketide natural products. However, the review does not report a single total synthesis in which the Cu-catalyzed asymmetric allylic alkylation with organomagnesium reagents served as the key step, despite citing over 200 references in this section. Has the Cu/phosphoramidite-catalyzed asymmetric allylic alkylation with Grignard reagents been demonstrated as the key step in a total synthesis, and if not, what practical limitations (functional group sensitivity of Grignard reagents, competing β-hydride elimination with alkyl-substituted electrophiles, incompatibility with protic functional groups) have prevented its deployment in complex settings?

severity: high

inference_tier: T2 [paper-grounded inference]

---

**V2-Q8**

loc: P48:Lcol:5-20 (p. 9634, section 5.1.3 Organoboron Reagents, Tang group Pd/L113 carbonylbenzoxazolidinone coupling; Scheme 52 discussion)

quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: The Pd/L113-catalyzed atroposelective Suzuki–Miyaura cross-coupling of carbonylbenzoxazolidinone 496 with arylboronic acids is cited as enabling "efficient total synthesis of several biaryl natural products," but the review does not name those natural products, report their yields, or describe how the axial chirality generated by the coupling was maintained through subsequent steps. Axially chiral biaryl natural products include gossypol, mastigophorene, ellagitannins, steganone, and michellamines — which specific targets were synthesized, and were they synthesized enantiopure using the catalytic cross-coupling as the sole stereodetermining step?

severity: medium

inference_tier: T2 [paper-grounded inference]

---

**V2-Q9**

loc: P44:Lcol:10-30 (p. 9630, section 4.1.4 Organoboron Reagents, Cu/L101-catalyzed allylic alkylation with simple 9-BBN reagents; Scheme 40)

quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: Scheme 40 (Cu/L101, 9-BBN reagents, 93% yield, 88% ee, tertiary center; 79% yield, 90% ee, quaternary center) is highlighted as demonstrating excellent chemoselectivity in the presence of aryl bromide. From a target-synthesis perspective, quaternary carbon centers bearing allylic substituents are present in numerous sesqui- and diterpene targets (e.g., terpestacin, platensimycin, ent-kaurene framework). Has this Cu/L101/9-BBN methodology been applied to any terpenoid target synthesis, and what is the upper bound on substrate complexity (molecular weight, number of stereocenters, protecting group requirements) that has been demonstrated for this catalytic system?

severity: medium

inference_tier: T2 [paper-grounded inference]

---

**V2-Q10**

loc: P57:Rcol:20-40 (p. 9643, reference section, refs 315–319 citing applications of Cu/TaniaPhos-directed allylic alkylation to natural product synthesis)

quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: The o-dppbz-directed stereospecific Cu-catalyzed allylic alkylation (Scheme 43, 414a → 415, >95% yield, 100% es, retention) is cited as having been applied to the synthesis of (+)-bourgeanic acid and (R,R,R)-α-tocopherol. For α-tocopherol (vitamin E), the stereocenter in question is a benzylic quaternary-adjacent position that is set by chemical resolution or asymmetric synthesis in current industrial processes. The review does not compare the step count, overall yield, or practicality of the Cu-catalyzed enantiospecific route versus the existing industrial syntheses of α-tocopherol. Is the Cu/o-dppbz approach to α-tocopherol competitive with established industrial routes in terms of step count and overall yield, and does it provide access to individual stereoisomers (e.g., (R,R,S)-α-tocopherol) not readily available from natural sources?

severity: medium

inference_tier: T2 [paper-grounded inference]

---

**V2-Q11**

loc: P36:Rcol:5-25 (p. 9622, section 4.1.4 Organoboron Reagents, Rh-catalyzed substitution with arylboronic acids using BINAP; Figure 71, nitroallyl acetate 347 + PhB(OH)₂ → 348, 97% ee)

quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: The Rh/BINAP-catalyzed allylic substitution of nitroallyl acetate 347 (Figure 71, 56% yield, 97% ee) accesses allylic amine precursors via in situ reduction of the nitro group. α-Amino acid and β-amino alcohol motifs generated by allylic amination are present in many pharmaceutical agents (e.g., oseltamivir, sitagliptin fragments, taxol side chain). The review does not report whether the nitro-group-bearing product 348 can be efficiently reduced to the amine without loss of stereochemical integrity under standard conditions (e.g., Zn/AcOH, H₂/Pd, Fe/AcOH), nor whether the Rh-catalyzed approach has been extended to electrophiles bearing additional nitrogen-protecting groups relevant to amino acid synthesis. Has compound 348 or a close analogue been elaborated to a biologically active amine target, and what is the demonstrated compatibility of the Rh/BINAP conditions with nitrogen-containing functional groups?

severity: medium

inference_tier: T2 [paper-grounded inference]

---

**V2-Q12**

loc: P14:Lcol:5-25 (p. 9600, section 2.3 Transition-Metal-Catalyzed Desymmetrization Reactions; general introduction)

quote: [REDACTED: see `loc:` above; full text in Tier 9]
question: Section 2.3 covers Ni-, Pd-, and Rh-catalyzed desymmetrization of meso-anhydrides and meso-dihalides as a route to enantiopure products, but the review does not compare this catalytic desymmetrization strategy with the competing asymmetric approach of using chiral auxiliary-controlled reactions or enzymatic desymmetrization for the same target class. For pharmaceutical synthesis, where scalability and cost-of-goods are critical, has any of the transition-metal-catalyzed desymmetrization reactions described in section 2.3 been operated at gram scale (>1 g of product) with catalyst loading ≤5 mol %, and have any of these methods been validated on the kilogram scale relevant to pharmaceutical process development?

severity: medium

inference_tier: T2 [paper-grounded inference]

---

### --- Overlaps with V1 ---

**V2-OV1** | overlaps_with: V1-Q4 | severity_V2: high | note: V1 questions whether there is direct mechanistic evidence for the precoordination of the amino group in PPFA-type ligands during Ni-catalyzed coupling of α-methylbenzyl Grignard 5; from the target-synthesis perspective this question is equally important because without a validated mechanistic model, rational ligand design for analogous couplings of more complex Grignard reagents derived from natural product intermediates is impossible, making the mechanistic gap a practical bottleneck as well as a scientific one.

**V2-OV2** | overlaps_with: V1-Q8 | severity_V2: high | note: V1 notes that the Ni¹/Ni³ mechanism for Fu-group α-bromo amide Negishi coupling is purely computational; from the target-synthesis perspective, this matters because the lack of experimental validation of the Ni oxidation state means that catalyst optimization for challenging substrates (e.g., β-branched or heterocycle-bearing amides) has no validated mechanistic basis, increasing the risk of empirical optimization failures in target-directed applications.

**V2-OV3** | overlaps_with: V1-Q14 | severity_V2: medium | note: V1 asks about functional group tolerance of the Cu/L101 allylic alkylation with 9-BBN reagents; the target-synthesis view elevates this to a high-priority question because quaternary carbon construction in terpenoid synthesis requires compatibility with ester, epoxide, and free alcohol groups that are routine in terpenoid natural product intermediates, and the cited competition experiment (aryl bromide chemoselectivity) does not constitute a functional group tolerance survey.

**V2-OV4** | overlaps_with: V1-Q13 | severity_V2: medium | note: V1 identifies the mechanistic basis for the inferiority of acyclic over cyclic allylic electrophiles in Ni-catalyzed asymmetric allylic substitution; from the target-synthesis lens, this translates directly into a synthetic planning limitation — the majority of acyclic terpenoid allylic stereocenters cannot reliably be set by this approach, which means the mechanistic gap identified by V1 directly excludes a large class of natural product targets.

**V2-OV5** | overlaps_with: V1-Q2 | severity_V2: low | note: V1 asks whether the KR vs. DYKAT ambiguity for the original Consiglio-Kumada 1973–1974 system has been resolved; from the target-synthesis perspective this has lower priority because the 1973–74 system delivers too low ee (15–38%) for practical target synthesis, so the mechanistic ambiguity, while intellectually important, does not currently impede any synthetic application.

---

> **Tier 8 redaction notice**: This file is a redacted copy of the corresponding Tier 3 / Tier 9 output. Verbatim source-paper quotations have been replaced by `[REDACTED: see source paper §<loc>; full text retained in Tier 9 reviewer-only deposit]` markers, preserving location references and our own analytical content. Bibliographic fields (title, authors, journal, year, DOI), analytical labels (`evidence_chain:` with B-/U-/A-/C- internal IDs), short technical terms, and our own analytical text are not redacted. The redaction was applied by `scripts/redact_for_tier8.py` and, for this version, by `scripts/build_paperA_R1_public.py` with `scripts/redact_source_ngram_runs.py` (scripts of the project repository; they are not deposited).
